Mark G. Lebwohl, MD, provides key takeaways and commentary on the results of the TOGETHER-PsO study, which looked at a combination therapy of ixekizumab (Taltz) and tirzepatide (Zepbound) in patients with both psoriasis and obesity.
advertisement
TOGETHER-PsO: Dual Therapy for Psoriasis and Obesity
Share
Save
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Recommended
Details
Overview
Mark G. Lebwohl, MD, provides key takeaways and commentary on the results of the TOGETHER-PsO study, which looked at a combination therapy of ixekizumab (Taltz) and tirzepatide (Zepbound) in patients with both psoriasis and obesity.
Title
Program Chapters
Segment Chapters
Playlist:
advertisement
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?